Clinical trials: Diffuse Scleroderma
Graft Versus Host Disease, Systemic Scleroderma
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
This randomized phase II trial is evaluating how well imatinib mesylate works compared to rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease (GVHD).
- Trial name
- NCT01309997
- Testing
- imatinib mesylate, rituximab
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Lee, Stephanie
Microstomia, Systemic Sclerosis
The Effect of a Home-based Orofacial Exercise Program on Oral Aperture of Systemic Sclerosis Patients
Systemic sclerosis is a systemic disease which may involve multiple organ systems and cause functional disabilities. Microstomia is one of the most common complications of the disease which may result in difficulties performing…
- Trial name
- NCT04336475
- Testing
- orofacial exercise program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Cukurova University
Systemic Scleroderma, Severe Systemic Sclerosis
Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis.
- Trial name
- NCT00622895
- Testing
- fludarabine phosphate, Mycophenolic Acid, tacrolimus
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Scleroderma, Systemic
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
ASSIST I was the first randomized trial in patients with scleroderma to not just slow disease progression but rather actually reverse it.
- Trial name
- DIScl2011 (NCT01445821)
- Testing
- Peripheral Blood Stem Cells, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
SYSTEMIC SCLERODERMA
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
Scleroderma is a systemic disorder categorized as an immunologically mediated disease that causes collagen deposition of skin and visceral organs.
- Trial name
- NCT00278525
- Testing
- standard of care, stem cell transplantation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Keloid, Alopecia Areata
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar
- Trial name
- NCT03630198
- Testing
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Systemic Lupus Erythematosus, Systemic Sclerosis
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
The purpose of this study is to determine if a reduced intensity (RI) (non-myeloablative) chemoimmunotherapy followed by Allogeneic Stem Cell Transplantation AlloSCT (matched family donors and matched unrelated cord blood donors)…
- Trial name
- NCT00684255
- Testing
- Reduced Intensity Allogeneic Transplant, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New York Medical College
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Scleroderma
Scleroderma Treatment With Autologous Transplant (STAT) Study
This phase II trial studies how well giving cyclophosphamide and anti-thymocyte globulin together followed by peripheral blood stem cell transplant (PBSCT) and mycophenolate mofetil works in treating patients with systemic…
- Trial name
- STAT (NCT01413100)
- Testing
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide
- Where
- 12 sites in United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center